ITGB4 and central nervous system cancer: Cell experiments for the first time reveal that the IDH1 mutation byproduct, D-2HG, effectively inhibits the ITGB4/PI3K/AKT pathway, thus exerting potent anti-glioma effects and offering insights into its mechanism of action, including its synergistic effect with TMZ.